Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges

por Hefazi, Mehrdad, Bolivar-Wagers, Sara, Blazar, Bruce R.
Publicado 2021

Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease

por Bolivar-Wagers, Sara, Larson, Jemma H., Jin, Sujeong, Blazar, Bruce R.
Publicado 2022

Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV

por Iwamoto, Nami, Patel, Bhavik, Song, Kaimei, Mason, Rosemarie, Bolivar-Wagers, Sara, Bergamaschi, Cristina, Pavlakis, George N., Berger, Edward, Roederer, Mario
Publicado 2021

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy

por Pennell, Christopher A, Campbell, Heather, Storlie, Meghan D, Bolivar-Wagers, Sara, Osborn, Mark J, Refaeli, Yosef, Jensen, Michael, Viaud, Sophie, Young, Travis S, Blazar, Bruce R
Publicado 2022

Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses

por Bolivar-Wagers, Sara, Loschi, Michael L., Jin, Sujeong, Thangavelu, Govindarajan, Larson, Jemma H., McDonald-Hyman, Cameron S., Aguilar, Ethan G., Saha, Asim, Koehn, Brent H., Hefazi, Mehrdad, Osborn, Mark J., Jensen, Michael C., Wagner, John E., Pennell, Christopher A., Blazar, Bruce R.
Publicado 2022